HC Wainwright & Co. has decided to maintain its Buy rating of Cabaletta Bio
and raise its price target from $15.00 to $17.00.
Shares of Cabaletta Bio are trading up 9.86% over the last 24 hours, at $13.48 per share.
A move to $17.00 would account for a 26.11% increase from the current share price.
About Cabaletta Bio
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.